AstraZeneca says preliminary data from a trial shows that its COVID-19 vaccine, Vaxzevria, generated an increase in antibodies against Omicron and other variants when given as a third booster dose. AstraZeneca country president Lotis Ramin joins us.
Visit our website for more #NewsYouCanTrust: https://www.cnnphilippines.com/
Follow our social media pages:
• Facebook: https://www.facebook.com/CNNPhilippines
• Instagram: https://www.instagram.com/cnnphilippines/
• Twitter: https://twitter.com/cnnphilippines
